SCOTTSDALE, Ariz., Oct. 10, 2008 (GLOBE NEWSWIRE) -- Medicis (NYSE:MRX - News) today announced the U.S. Food and Drug Administration (FDA) has approved its premarket approval application (PMA) supplement, based on clinical data which highlights RESTYLANE(R)'s duration effect up to 18 months in 97% of patients with repeated treatment. The RESTYLANE(R) package insert will be amended to include the study results. The Company anticipates using this information in its promotional activities.
